What the business is, and whether it's a good one at a fair price.
Imports and markets AstraZeneca's prescription drugs in India across three therapy areas. Oncology generated Rs 16,101 million in FY26 (up 44% year on year), led by cancer drugs such as Enhertu and Tagrisso sold to hospital oncologists. Biopharmaceuticals contributed Rs 5,243 million (up 7.2%), covering biologic medicines such as Fasenra. Rare Disease was Rs 215 million, up sevenfold. The company exited its Bengaluru manufacturing operations during the year, so all products are now imported and distributed through a marketing organisation of 760 permanent employees. Eleven new regulatory approvals were secured in FY26, including label extensions for Enhertu (neoadjuvant HER2-positive breast cancer) and Fasenra (Hypereosinophilic Syndrome). Employee costs are the largest stated operating expense at 11.6% of revenue, followed by other operating expenses at 16.2%. The business carries exposure to price control litigation under DPCO 2013 - NPPA has issued demand notices alleging overcharging on Symbicort Turbuhaler 160/4.5 (Rs 148.66 crore inclusive of interest) and Betaloc-50 tablets (Rs 79.97 lakh), both of which the company is reviewing.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from ASTRAZENECA PHARMA IND LT's filed financials and exchange disclosures
ASTRAZENECA PHARMA IND LT is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol ASTRAZEN.
Yes. Over the trailing twelve months ASTRAZENECA PHARMA IND LT reported a net profit of ₹170 Cr on revenue of ₹2,432 Cr.
Yes. The dividend yield is 0.47% at the current price. It paid out 43% of its profit as dividend in FY26.
Effectively yes. It holds ₹448 Cr more cash than debt. Debt stands at 0.00× equity.
On trailing P/E, ASTRAZENECA PHARMA IND LT ranks 155 of 169 in Pharmaceuticals — cheaper than 8% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session ASTRAZENECA PHARMA IND LT moves 0.85% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by ASTRAZENECA PHARMA IND LT appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
